Fixing CRISPR | Biotech from Bench to Business | GEN

CRISPR/Cas9’s off-target effects have raised serious concerns about its ultimate applicability to human therapies.See it on Scoop.it, via Viruses and Bioinformatics from Virology.uvic.ca
Fixing CRISPR | Biotech from Bench to Business | GEN
Source: Viral Bioinformatics

You may also like...